



ELSEVIER
SAUNDERS

Clin Lab Med 25 (2005) 465–472

CLINICS IN
LABORATORY
MEDICINE

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Adenofibroma, metanephric, 388–390
- Adenoma(s), renal
classification of, 233, 235–239
metanephric, 292, 379–384
papillary, 284, 286
- Adrenal glands, renal cell carcinoma spread to, 444
- Adrenal rests, 232–233
- AE1/AE3, in renal cell carcinoma, 249, 251
- Albarran and Imbert renal tumor classification, 234
- Algorithms, prognostic, for renal cell carcinoma surgical treatment, 452–456
- Alpha-TFEB* gene fusion, in renal carcinoma, 370–375
- Alveolar soft part sarcoma, renal, 363–367, 369–370
- Anaplasia, in nephroblastoma, 348–350
- Angiomyolipoma, epithelioid, renal, 331, 405–408
- Antimitochondrial antibody stain, for oncocytoma, 320
- Aphidicolin-inducible fragile site, mutations at, in papillary renal cell carcinoma, 285
- ASPL-TFE3* gene fusion, in renal carcinoma, 364–366, 369–370

B

- Bcl-2 protein, in oncocytoma, 320
- Beckwith-Wiedemann syndrome, nephroblastoma in, 343, 346
- Bell, Elexious Thompson, renal tumor classification of, 235–236
- BHD* gene, mutations of, 270

- Binney renal tumor classification, 233
- Birt-Hogg-Dubé syndrome, renal neoplasms in, 269–270, 328–329
oncocytosis, 326
renal cell carcinoma, 269–270
- Bloom syndrome, nephroblastoma in, 343, 346
- Botryoid nephroblastoma, 367

C

- Cam 5.2, in renal cell carcinoma, 249
- Carcinomas, renal cell. *See* Renal cell carcinoma(s).
- CD10, in renal cell carcinoma, 248–250, 252–253
- CD14, in renal cell carcinoma, 252
- CD15, in renal cell carcinoma, 249–250, 254–255
- CD117, in renal cell carcinoma, 249, 251–254
- Chemotherapy, for nephroblastoma, 352
- Chromophobe renal cell carcinoma, 321–324
eosinophilic variant, 321–324
differential diagnosis of, 331–334
molecular diagnostic techniques for, 288–289
epidemiology of, 321
granular-appearing cells in, 322
gross pathology of, 321
immunohistochemical markers for, 252–255, 323
in Birt-Hogg-Dubé syndrome, 328–329
microscopic pathology of, 321–323, 436
molecular diagnostic techniques for, 288–289, 323
oncocytomas and, 326–328
polygonal type, 322
prognosis for, 418, 439–440, 451–452

Chromophobe (*continued*)
 sarcomatoid differentiation or
 transformation of, 323, 441
 versus clear cell renal carcinoma with
 eosinophilic cells, 334

CK7
 in metanephric adenoma, 380
 in renal cell carcinoma, 249, 253–255

CK8, in renal cell carcinoma, 253, 311–312

CK18, in clear cell renal cell carcinoma,
 311–312

CK19, in renal cell carcinoma, 253,
 311–312

CK20, in renal cell carcinoma, 254–255

Clear cell renal cell carcinoma, **305–316**
 clinical features of, 305–306
 compact-alveolar pattern of, 308–309
 cytology of, 310–311
 differential diagnosis of, 312
 eosinophilic variant, 329–334
 epidemiology of, 305
 familial, 260–265
 gross pathology of, 306–307
 immunohistochemical markers for,
 248–250, 253
 in Birt-Hogg-Dubé syndrome,
 269–270, 328–329
 in tuberous sclerosis, 271–272
 microcystic pattern of, 309–310
 microscopic pathology of, 307–310,
 434
 molecular diagnostic techniques for,
 281–283, 311–312
 prognosis for, 418, 439–440, 451–452
 sarcomatoid differentiation of, 441
 tubular pattern of, 309

Clear cell sarcoma, renal, versus
 metanephric stromal tumor, 387

CLTC-TFE3 gene fusion, in renal
 carcinoma, 364, 367

Collecting duct carcinoma
 immunohistochemical markers for,
 251
 low-grade (mucinous, tubular, and
 spindle cell carcinoma), 393–398
 microscopic pathology of, 437–438
 molecular diagnostic techniques for,
 289–291
 oncocytic features of, 330
 prognosis for, 419
 versus tubulocystic carcinoma,
 399–400

Compact-alveolar pattern, of clear cell renal
 cell carcinoma, 308–309

Comparative genetic hybridization, for
 renal neoplasms, 280
 chromophobe renal cell carcinoma,
 288
 oncocytoma, 288

Cystic nephroma, 354–355

Cystic partially-differentiated
 nephroblastoma, 354–355

Cytokeratin. *See also* CK.
 in renal cell carcinoma, 249, 251,
 311–312

Cytology, in clear cell renal cell carcinoma,
 310–311

D

Denys-Drash syndrome, nephroblastoma
 in, 343–344

DIRC2 gene, mutations of, in familial clear
 cell renal cell carcinoma, 264

E

E-cadherin, in renal cell carcinoma,
 249–251, 253–254

Edwards syndrome (trisomy 18),
 nephroblastoma in, 343, 346

Electron microscopy, in renal oncocytoma,
 319

Eosinophilic variant
 of chromophobe renal cell carcinoma,
 288–289, 321–324, 331–334
 of clear cell renal cell carcinoma,
 329–334

Epithelial membrane antigen
 in metanephric adenoma, 380
 in renal cell carcinoma, 249, 252–253,
 323

Epithelioid angiomyolipoma, renal, 331,
 405–408

Ewing renal tumor classification, 234

EWS-FLII gene fusion, in primitive
 neuroectodermal tumor, 408–410

F

Familial nephroblastoma, 345

Familial renal cell carcinomas, **259–277**
 clear cell, 260–265
 in Birt-Hogg-Dubé syndrome, 269–270
 in von Hippel-Lindau disease, 259–263
 leiomyomatosis with, 267–269

- oncocytoma and, 270–271
- papillary, 265–267, 272
- tuberous sclerosis and, 271–272
- with chromosome 3 translocation, 264
- FH* gene, mutations of, in hereditary leiomyomatosis with renal cell carcinoma, 267–269
- FHIT* gene, mutations of, in clear cell renal cell carcinoma, 264, 282
- Fine needle aspiration, in clear cell renal cell carcinoma, 310–311
- FISH. *See* Fluorescent in situ hybridization (FISH).
- Fite renal tumor classification, 234
- FLII–EWS* gene fusion, in primitive neuroectodermal tumor, 408–410
- Fluorescent in situ hybridization (FISH), for renal neoplasms, 280, 282
 - chromophobe renal cell carcinoma, 288, 323
 - oncocytoma, 288
 - papillary renal cell carcinoma, 286
- Fragile histidine triad gene, mutations of, in clear cell renal cell carcinoma, 264, 282
- Fuhrman grade, of renal cell carcinoma nuclei, 448–450
- Fumarate hydratase, defects of, in hereditary leiomyomatosis with renal cell carcinoma, 267–269

G

- Garceau renal tumor classification, 233
- Grawitz, Paul Albert, renal tumor classification of, 232–233, 235

H

- Hale's colloidal iron stain
 - in chromophobe renal cell carcinoma, 323
 - in renal oncocytoma, 319–320
- Heidelberg-Rochester Classifications of 1997, for renal tumors, 235–236, 238–242
- Hepatocyte growth factor/scatter factor, in hereditary papillary renal cell carcinoma, 265–267
- Hereditary leiomyomatosis, renal cell carcinoma with, 267–269
- Hereditary papillary renal cell carcinoma, 265–267, 285

HMB45

- in epithelioid angiomyolipoma, 406–407
- in translocation carcinoma, 370, 373

Horseshoe kidney, nephroblastoma in, 341–342

Hypoxia-inducible factor, regulation of, in von Hippel-Lindau disease, 262–263

I

- Immunohistochemical markers, for renal neoplasms
 - chromophobe renal cell carcinoma, 252–253, 323
 - clear cell renal cell carcinoma, 248–250, 311–312
 - collecting duct carcinoma, 251
 - epithelioid angiomyolipoma, 406–407
 - metanephric stromal tumor, 386
 - mixed epithelial and stromal tumor, 404
 - mucinous, tubular, and spindle carcinoma, 400–401
 - nephroblastoma, 351–352
 - oncocytoma, 253–255, 320
 - papillary renal cell carcinoma, 250–251
 - primitive neuroectodermal tumor, 410
 - renal cell carcinomas, **247–257**
 - synovial sarcoma, 412
 - translocation carcinoma, 367, 369, 375
 - tubulocystic carcinoma, 400–401
- Intralobar nephrogenic rests, 353–354, 387

K

- Kidney
 - horseshoe, nephroblastoma in, 341–342
 - neoplasms of. *See* Renal neoplasms.

L

- Leiomyomatosis, hereditary, renal cell carcinoma with, 267–269
- Li-Fraumeni syndrome, nephroblastoma in, 343
- Loss of heterozygosity analysis, for renal neoplasms, 279–280
 - chromophobe renal cell carcinoma, 288–289
 - clear cell renal cell carcinoma, 281–283
 - collecting duct carcinoma, 289–290
 - oncocytoma, 288–289
 - papillary renal cell carcinoma, 287–288
- Lymph nodes, renal cell carcinoma extension into, 445–446

M

- Mainz Classification of 1986, for renal tumors, 235, 237–239
- Mayo Clinic, renal cell carcinoma prognostic algorithm and reporting form of, 455–456, 459–460
- Medullary carcinoma, renal, 331, 419
- Melan A, in translocation carcinoma, 370
- Melicow renal tumor classification, 233–234
- Memorial Sloan-Kettering Cancer Center, renal cell carcinoma prognostic algorithm of, 452–453
- Mesothelioma, renal cell carcinoma with, 248
- c-MET* gene, mutations of, in hereditary papillary renal cell carcinoma, 265–267, 285
- Metanephric neoplasms, **379–392**
adenofibroma, 388–390
adenoma, 292, 379–384
stromal, 384–387
- Metastasis
from metanephric adenoma, 383
from nephroblastoma, 351–352
from renal cell carcinoma, 441–442, 445–447, 458
from translocation renal carcinomas, 365
- α -Methylacetyl-CoA racemase, in renal cell carcinoma, 249, 251, 253
- Microcystic pattern, of clear cell renal cell carcinoma, 309–310
- Microphthalmia transcription factor, in translocation renal carcinoma, 370, 374–375
- Microsatellite analysis, for renal neoplasms, 280
chromophobe renal cell carcinoma, 288
clear cell renal cell carcinoma, 281
oncocytoma, 288
- MiRF/TFE family translocation carcinomas, renal, 363–370
- Mixed epithelial and stromal tumor, renal, 402–405
- Molecular techniques, for renal neoplasms, **279–303**
chromophobe renal cell carcinoma, 288–289
clear cell renal cell carcinoma, 281–283

- collecting duct carcinoma, 289–291
metanephric adenoma, 292
oncocytoma, 288–289, 320
papillary adenoma, 284, 286
papillary renal cell carcinoma, 283–288
renal cell carcinoma with Xp11.2 translocations, 292–294
sarcomatoid carcinoma, 291–292

Monosomy, of various chromosomes, in collecting duct carcinoma, 289–290

MUC1 protein, in renal cell carcinoma, 249–251

Mucinous, tubular, and spindle cell carcinoma, 393–398

N

Necrosis, in renal cell carcinoma, prognostic value of, 450–452

Neoplasms, renal. *See* Renal neoplasms.

Nephrectomy, specimen handling and reporting after
partial, 426–427
radical, 422–425

Nephroblastic neoplasms, **341–361**. *See also* Nephroblastoma.
classification of, 342
cystic partially-differentiated nephroblastoma, 354–355
nephroblastomatosis, 352–354
nephrogenic rests, 352–354

Nephroblastoma
anaplastic, 348–350
botryoid, 367
clinical course of, 352
clinical features of, 345–346
cystic partially-differentiated, 354–355
development from nephrogenic rests, 354
distribution of, 341–342
epidemiology of, 341
familial disposition to, 345
gross pathology of, 346–347
immunohistochemical markers for, 351–352
metastatic, 351–352
microscopic pathology of, 347–350
multicentric, 345
nephrogenic rests and, 345
nuclear unrest in, 350
outcome of, 352
pathogenesis of, 342–345
pathology of, 346–352
posttherapy changes in, 351
prognosis for, 348–350

- staging of, 346–347
- syndromes associated with, 342–345
- treatment of, 352
- versus metanephric adenoma, 382–383
- Nephroblastomatosis, 352–354
- Nephrogenic rests, 352–354
 - multicentric nephroblastoma and, 345
 - versus metanephric stromal tumor, 387
- Nephroma, congenital mesoblastic, versus mixed epithelial and stromal tumor, 405
- Neuroblastoma, oncocytoid renal cell carcinoma with, 331
- Neurofibromatosis, type 1, nephroblastoma in, 343
- Non-O-TFE3* gene fusion, in renal carcinoma, 364, 367, 369
- North American National Wilms Tumor Study Group staging system, 346
- Nuclear grade, of renal cell carcinoma, 419, 447–450
- Nuclear unrest, in nephroblastoma, 350

O

- Oncoblasts, microscopic appearance of, 319
- Oncocytes, microscopic appearance of, 318–319
- Oncocytic renal neoplasms, **317–339**.
 - See also* Chromophobe renal cell carcinoma; Oncocytomas, renal.
 - differential diagnosis of, 329–334
 - hybrid, 326–327
 - in Birt-Hogg-Dubé syndrome, 328–329
 - oncocytosis, 324–326
- Oncocytomas, renal, 318–321
 - atypical features in, 319
 - chromophobe renal cell carcinoma and, 326–328
 - differential diagnosis of, 331–334
 - epidemiology of, 318
 - familial, 270–271
 - gross pathology of, 318
 - histology of, 318–320
 - immunohistochemical markers for, 253–255, 320
 - in Birt-Hogg-Dubé syndrome, 328–329
 - metachronous, 326
 - molecular diagnostic techniques for, 288–289, 320
 - multi-focal, 324–326
 - prognosis for, 320–321
 - tubulocystic pattern of, 318
- Oncocytosis, renal, 324–326

P

- Pancytokeratin, in renal cell carcinoma, 253
- Papillary renal cell adenoma, 284, 286
- Papillary renal cell carcinoma
 - familial, 265–267, 272
 - hereditary, 265–267, 285
 - immunohistochemical markers for, 250–251, 381–383
 - in Birt-Hogg-Dubé syndrome, 328–329
 - microscopic pathology of, 434–435
 - molecular diagnostic techniques for, 283–288
 - oncocytic features of, 330
 - papillary thyroid carcinoma with, 272
 - prognosis for, 418–419, 439–440, 451
 - sarcomatoid differentiation of, 441
 - versus clear cell renal cell carcinoma, 312
 - versus metanephric adenoma, 380–382
- Papillary thyroid carcinoma, papillary renal cell carcinoma with, 272
- Parvalbumin
 - in oncocytoma, 320
 - in renal cell carcinoma, 252–253, 323
- Pediatric patients, renal tumors in. *See also* Nephroblastoma.
 - classification of, 342
- Perilobar nephrogenic rests, 353
- Perlman syndrome, nephroblastoma in, 343, 346
- Polymerase chain reaction, for translocation-associated gene fusions, 373
- PRCC-TFE3* gene fusion, in renal carcinoma, 364–365, 368–370
- Primitive neuroectodermal tumor, renal, 408–410
- PSF-TFE3* gene fusion, in renal carcinoma, 364, 367

R

- Ras association domain family 1A gene, mutations of, in clear cell renal cell carcinoma, 282
- RASSF1A* gene, mutations of, in clear cell renal cell carcinoma, 282
- Rayer, Pierre François Olive, renal tumor classification of, 231–232
- RB* gene, mutations of, in collecting duct carcinoma, 289

- Renal cell carcinoma(s)
 adrenal involvement in, 444
 chromophobe. *See* Chromophobe renal cell carcinoma.
 classification of, 235, 237–239, 418–419, 434–447, 458
 clear cell. *See* Clear cell renal cell carcinoma.
 completeness of resection of, 420
 epidemiology of, 305
 familial. *See* Familial renal cell carcinomas.
 histologic types of, 418–419, 434–440
 immunohistochemical markers for, **247–257**
 mesothelioma with, 248
 metastasis from, 441–442, 445–447, 458
 microscopic vascular invasion of, 420–421
 nuclear grade of, 419, 447–450
 oncocytoid, neuroblastoma with, 331
 outcome prediction models for, 421–422
 papillary. *See* Papillary renal cell carcinoma.
 perinephric fat involvement in, 444–445
 primary tumor characteristics in, 442, 444–445, 447
 prognosis for, 417–422
 after surgical treatment, **433–464**
 risk factors for, 305
 specimen handling and reporting for, **417–432**
 frozen section, 428–429
 in partial nephrectomy, 426–427
 in radical nephrectomy, 422–425
 morcellated, 427–428
 needle core biopsy, 428
 prognostic factors in, 417–422
 staging of, 420
 surgical treatment of
 prognosis after, **433–464**
 algorithms for, 452–456
 histologic subtype and, 434–440
 necrosis and, 450–452
 nuclear grade and, 447–450
 primary tumor size and, 447
 reporting form for, 459–460
 sarcomatoid differentiation and, 440–441
 TNM classification and, 441–447, 458
 specimen handling and reporting for, 422–427
 tumor size and, 419–420
 with sarcomatoid elements, 291–292
 with Xp11.2 translocation, 292–294, 363–370
- Renal cell carcinoma marker, 247–250, 252–253, 370
- Renal neoplasms. *See also specific types.*
 classification of
 history of, **231–246**
 nephroblastic, 342
 papillary renal cell adenoma, 284
 pediatric, 342
 renal cell carcinoma, 235, 237–239, 418–419, 434–447, 458
 clear cell renal cell carcinoma. *See* Clear cell renal cell carcinoma.
 epithelial, **279–303**
 epithelioid angiomyolipoma, 331, 405–408
 immunohistochemical markers for.
 See specific tumors,
 immunohistochemical markers for.
 metanephric, **379–392**
 mixed epithelial and stromal, 402–405
 molecular diagnosis of, **279–303**
 mucinous, tubular, and spindle cell carcinoma, 393–398
 nephroblastic, **341–361**
 oncocytic, **317–339**. *See also* Oncocytomas, renal.
 primitive neuroectodermal, 408–410
 rare, **393–416**
 renal cell carcinoma. *See* Renal cell carcinoma(s); *specific types.*
 specimen handling and reporting for, **417–432**
 synovial sarcoma, 411–413
 translocation carcinomas, **363–378**
 tubulocystic carcinoma, 393–395, 398–402
- Renal vein, renal cell carcinoma extension into, 445
- Restriction fragment length polymorphism analysis, in renal neoplasms
 chromophobe renal cell carcinoma, 288
 clear cell renal cell carcinoma, 281
 oncocytoma, 288
- Rhabdoid component, of clear cell renal cell carcinoma, 329–330
- Ron* gene, mutations of, in oncocytoma, 320
- S**
- Sarcoma, renal
 alveolar soft part, 363–367, 369–370

clear cell, versus metanephric stromal tumor, 387
synovial, 411–413

Sarcomatoid carcinoma, renal
molecular diagnostic techniques for, 291–292
prognosis for, 419, 440–441

Simpson-Golabi-Behmel syndrome, nephroblastoma in, 343, 346

Sotos syndrome, nephroblastoma in, 343, 346

Specimen handling and reporting, for renal cell carcinoma. *See* Renal cell carcinoma(s), specimen handling and reporting for.

Spindle cell carcinoma, renal, 393–398

SSIGN score, for renal cell carcinoma prognosis, 455–456

Staging
of nephroblastoma, 346
of renal cell carcinoma, 420, 441–442

Stromal metanephric neoplasms, 384–387

Synovial sarcoma, of kidney, 411–413

T

TFE3 gene, mutations of, in renal cell carcinoma, 292–294

TFE3 gene fusions, in renal carcinoma, 364–370

TFEB-Alpha gene fusion, in renal carcinoma, 370–375

Thoenes, Wolfgang Carl, renal tumor classification of, 237, 239

Thyroid carcinoma, papillary, papillary renal cell carcinoma with, 272

TNM classification, of renal cell carcinoma, 441–442

Translocation renal neoplasms carcinomas, **363–378**
familial clear cell renal cell carcinoma, 264
Xp11.2, 292–294, 364–370
primitive neuroectodermal tumor, 408–410
synovial sarcoma, 411–413

Trisomy 7, in papillary renal cell carcinoma, 285

Trisomy 17, in papillary renal cell carcinoma, 285

Trisomy 18 (Edwards syndrome), nephroblastoma in, 343, 346

TSC genes, mutations of, in tuberous sclerosis, 271–272

Tuberous sclerosis, molecular genetics of, 271–272

Tubular pattern, of clear cell renal cell carcinoma, 309

Tubulocystic carcinoma, 393–395, 398–402

Tubulocystic pattern, of oncocytoma, 318

Tumors, renal. *See* Renal neoplasms.

U

Union Internationale Contre le Cancer/
American Joint Committee on Cancer classification, of renal cell carcinoma, 434–440

University of California–Los Angeles, renal cell carcinoma prognostic algorithm of, 453–455

V

Vena cava, inferior, renal cell carcinoma extension into, 445

VHL gene mutations
in clear cell renal cell carcinoma, 306
in von Hippel-Lindau disease, 261–263, 281–282

Vimentin
in clear cell renal cell carcinoma, 253–255
in primitive neuroectodermal tumor, 410
in renal cell carcinoma, 248, 250, 253

Virchow renal tumor classification, 232

von Hippel-Lindau disease, molecular genetics of, 259–263, 281–282

W

WAGR (Wilms' tumor, aniridia, genitourinary malformation, mental retardation), 342–344

Weichselbaum and Greenish, renal tumor classification of, 233

Wilms' tumor. *See* Nephroblastoma.

World Health Organization, renal tumor
classification of, 235, 238, 242–244

WT1 gene, mutations of
nephroblastoma in, 342–344
nephrogenic rests in, 353

WT2 gene, mutations of
nephroblastoma in, 344–345
nephrogenic rests in, 353

X

Xp11 translocation carcinoma, renal,
292–294, 363–370

Y

Y chromosome, loss of, in renal papillary
adenoma, 286